Vitamina D3 Plus 3.000 IU - 60 softgel

Studio randomizzato. Importance In a phase 2 randomized clinical trial, high-dose vitamin D3 added to standard treatment improved progression-free survival (PFS) compared with standard-dose vitamin D3 in patients with metastatic colorectal cancer (mCRC). Objective To determine if high-dose vitamin D3 added to standard chemotherapy improves outcomes in patients with previously untreated mCRC. Design, setting, and participants Double-blind phase 3 randomized clinical trial enrolling 455 patients with previously untreated mCRC, conducted in the US through the National Clinical Trials Network from October 2019 to December 2022 (database freeze: July 15, 2024). Interventions mFOLFOX6 (modified FOLFOX6 [5-fluorouracil, leucovorin, oxaliplatin]) or FOLFIRI (5-fluorouracil, leucovorin, irinotecan) plus bevacizumab every 2 weeks with either high-dose vitamin D3 (8000 IU daily × 14 days as loading dose followed by 4000 IU daily) or standard-dose

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Meta-analisi. Background The immunomodulatory role of vitamin D3 in autoimmune diseases is widely hypothesized, but its therapeutic efficacy remains contested. This meta-analysis quantifies the effect of vitamin D3 supplementation on biochemical, endocrine, and inflammatory parameters across various autoimmune conditions. Methods We systematically searched five databases for randomized controlled trials (RCTs) comparing vitamin D3 to placebo/control in autoimmune disease patients. Data from 27 RCTs (n = 1864) were pooled using a random-effects model. Subgroup analyses were conducted based on disease type, dosage, and duration. Results Vitamin D3 supplementation significantly increased serum 25(OH)D levels (WMD: 53.01 nmol/L, 95% CI: 36.29-69.73, p Conclusion Vitamin D3 effectively corrects deficiency and exerts modest, systemic anti-inflammatory effects in autoimmune patients. Its impact is context-dependent, influenced by treatment dur

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Background Vitamin D deficiency is linked to Parkinson disease (PD) pathogenesis; however, clinical trial results remain inconclusive. Thus, in this study, we aimed to evaluate the prevalence of vitamin D deficiency in Thai patients with PD and the efficacy of vitamin D3 supplementation on clinical outcomes in a tropical, sun-abundant region. Methods In this randomized controlled trial, we enrolled 60 patients with PD and 60 healthy controls. Patients with PD were randomized 1:1 to receive 2000 IU/d of vitamin D3 or no additional treatment (control) for 12 weeks. Primary outcomes included changes in MDS-UPDRS, Hoehn and Yahr (mH&Y), Thai Mini-Mental State Examination, and PDQ-39 scores. The secondary outcome was the prevalence of vitamin D deficiency (25(OH)D Results At baseline, vitamin D deficiency was significantly more prevalent in patients with PD than in healthy controls (23.2% vs 10.0%, P = .046). After 12 we

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Importance Observational studies have reported associations between pregnancy vitamin D levels and offspring cognition, but no randomized clinical trial (RCT) has investigated the effect of high-dose vitamin D3 supplementation in pregnancy on offspring cognition into middle childhood. Objective To assess whether high-dose vitamin D3 supplementation during pregnancy is associated with improved offspring cognition at age 10 years. Design, setting, and participants This is a post hoc secondary analysis of the blinded, placebo-controlled Copenhagen Prospective Studies on Asthma in Childhood 2010 RCT conducted from March 4, 2009, to November 17, 2010. The cohort included 700 mother-child pairs from Denmark, of whom 623 were randomized. Exclusion criteria were vitamin D intake above 600 IU/d; endocrine, kidney, or heart disease; and insufficient Danish language proficiency. Cognitive assessments were conducted for the off

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Meta-analisi. Background Multiple sclerosis (MS) is a chronic immune-mediated neurodegenerative disorder of the central nervous system and a leading cause of disability among young adults. The disease exhibits considerable heterogeneity in clinical progression, with some patients experiencing more aggressive disease activity and a rapid decline in quality of life. Vitamin D plays a key role in immune regulation, and evidence suggests that its deficiency constitutes a significant environmental risk factor for immune-mediated conditions such as MS. While there are controversies regarding the role of serum 25(OH)D in MS as well as vitamin D3 supplements in controlling relapse and disability improvement during treatment. Therefore, our current meta-analysis aims to examine the relationship between serum 25(OH)D levels-and their modulation through supplementation-and multiple sclerosis. Methods Comprehensive literature review was performed f

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Importance Achieving and maintaining a serum 25-hydroxyvitamin D (25[OH]D) level of 40 ng/mL or higher, compared with 20 to 30 ng/mL, may lower diabetes risk among adults with prediabetes. It is not known whether a genetically defined subgroup is more likely to experience benefits from targeting higher 25(OH)D levels with vitamin D3 supplementation. Objective To assess the role of common polymorphisms of the vitamin D receptor (VDR) in the association between supplementation with 4000 IU/d of vitamin D3 and the risk of diabetes among adults with prediabetes. Design, setting, and participants This genetic association study conducted a VDR genotype analysis of 3 common polymorphisms-ApaI, BsmI, and FokI-among 2098 participants in the Vitamin D and Type 2 Diabetes (D2d) clinical trial with available intratrial 25(OH)D levels and genotyping. The D2d trial was conducted from October 1, 2013, to November 28, 2018, with st

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.